These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6468241)

  • 1. Bismuth subsalicylate--an aid to the diagnosis and treatment of reflux esophagitis.
    Bernstein RK
    Diabetes Care; 1984; 7(4):404-5. PubMed ID: 6468241
    [No Abstract]   [Full Text] [Related]  

  • 2. Bismuth subsalicylate reduces peptic injury of the oesophagus in rabbits.
    Tay HP; Chaparala RC; Harmon JW; Huesken J; Saini N; Hakki FZ; Schweitzer EJ
    Gut; 1990 Jan; 31(1):11-6. PubMed ID: 2108076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bismuth subsalicylate in the treatment of H2 blocker resistant duodenal ulcers: role of Helicobacter pylori.
    Wagner S; Gebel M; Haruma K; Bär W; Lange P; Freise J; Gladziwa U; Schmidt FW
    Gut; 1992 Feb; 33(2):179-83. PubMed ID: 1347278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De-Nol in the treatment of reflux esophagitis.
    Balan G; Săndulescu E; Cijevschi C; Stanciu R; Darwish R; Stanciu C
    Rev Med Chir Soc Med Nat Iasi; 1989; 93(1):67-70. PubMed ID: 2682898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of bismuth subsalicylate in relieving symptoms of indigestion.
    Hailey FJ; Newsom JH
    Arch Intern Med; 1984 Feb; 144(2):269-72. PubMed ID: 6365007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology of gastrointestinal infections: the role of bismuth subsalicylate. Scottsdale, Arizona, 11-14 February 1988. Proceedings.
    Rev Infect Dis; 1990; 12 Suppl 1():S1-119. PubMed ID: 2305172
    [No Abstract]   [Full Text] [Related]  

  • 7. Collagenous colitis treated successfully with bismuth subsalicylate.
    Amaro R; Poniecka A; Rogers AI
    Dig Dis Sci; 2000 Jul; 45(7):1447-50. PubMed ID: 10961728
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevention of diarrhea caused by enterotoxigenic Escherichia coli: lessons learned with volunteers.
    Graham DY; Evans DG
    Rev Infect Dis; 1990; 12 Suppl 1():S68-72. PubMed ID: 2406859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inadvertent exaggerated anticoagulation following use of bismuth subsalicylate in an enterally fed patient receiving warfarin therapy.
    Bingham AL; Brown RO; Dickerson RN
    Nutr Clin Pract; 2013 Dec; 28(6):766-9. PubMed ID: 24163322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pink Prescribing: Bismuth Subsalicylate; History, Actions, Risks, and Future Use.
    OʼMalley PA
    Clin Nurse Spec; 2020; 34(2):45-47. PubMed ID: 32068631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Addition of bismuth subsalicylate to triple eradication therapy for Helicobacter pylori infection: efficiency and adverse events].
    Hinostroza Morales D; Díaz Ferrer J
    Rev Gastroenterol Peru; 2014; 34(4):315-20. PubMed ID: 25594755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bismuth subsalicylate prophylaxis of Cryptosporidium parvum infection in immunodeficient mice.
    Greenfield RA; Mosier DA; Crawford DL; Abrams VL; Kuhls TL
    J Eukaryot Microbiol; 1996; 43(5):69S. PubMed ID: 8822865
    [No Abstract]   [Full Text] [Related]  

  • 13. Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli-induced diarrhea in volunteers.
    Graham DY; Estes MK; Gentry LO
    Gastroenterology; 1983 Nov; 85(5):1017-22. PubMed ID: 6352386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of loperamide with bismuth subsalicylate for the treatment of acute travelers' diarrhea.
    Johnson PC; Ericsson CD; DuPont HL; Morgan DR; Bitsura JA; Wood LV
    JAMA; 1986 Feb; 255(6):757-60. PubMed ID: 3944976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin and bismuth subsalicylate.
    Levy G
    Am J Dis Child; 1993 Dec; 147(12):1281. PubMed ID: 8249944
    [No Abstract]   [Full Text] [Related]  

  • 16. Which place for bismuth subsalicylate in the treatment of enteric infections?
    Guarino A; Bruzzese E
    Acta Paediatr; 2001 Jun; 90(6):601-4. PubMed ID: 11440089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
    Chey WD; Fisher L; Elta GH; Barnett JL; Nostrant T; DelValle J; Hasler WL; Scheiman JM
    Am J Gastroenterol; 1997 Sep; 92(9):1483-6. PubMed ID: 9317068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards a structural understanding of the anti-ulcer and anti-gastritis drug bismuth subsalicylate.
    Andrews PC; Deacon GB; Forsyth CM; Junk PC; Kumar I; Maguire M
    Angew Chem Int Ed Engl; 2006 Aug; 45(34):5638-42. PubMed ID: 16865763
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of aluminum hydroxide/magnesium hydroxide antacid and bismuth subsalicylate on gastric pH in horses.
    Clark CK; Merritt AM; Burrow JA; Steible CK
    J Am Vet Med Assoc; 1996 May; 208(10):1687-91. PubMed ID: 8641951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of a tetracycline and Pepto-Bismol interaction in the management of Helicobacter pylori-induced peptic ulcer disease.
    Tkach CL; Ariano RE
    Ann Pharmacother; 1998 Mar; 32(3):387. PubMed ID: 9533072
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.